The main effects of FBG are consistent with prior work that has found higher regional CBF, particularly in the MTL, in participants at risk for progression to AD (e.g., APOE ɛ4 carriers, those with subtle cognitive decline), but who are not yet considered cognitively impaired (Bangen et al., 2012; Fleisher et al., 2009; Thomas et al., 2021). The gene discussed is APOE; the disease is Alzheimer disease.